Highly Efficient and Highly Enantioselective
Asymmetric Hydrogenation of Ketones with
TunesPhos/1,2-Diamine-Ruthenium(II)
Complexes
SCHEME 1. Structure of Aprepitant
†
†
‡
†
Wei Li, Xianfeng Sun, Le Zhou, Guohua Hou,
†
,†
Shichao Yu, and Xumu Zhang*
Department of Chemistry and Chemical Biology &
Pharmaceutical Chemistry, Rutgers, The State UniVersity of
New Jersey, Piscataway, New Jersey 08854, and College of
Science, Northwest A&F UniVersity, Yangling, Shaanxi
4
5
a few analogue ligands, such as PhanePhos, P-Phos, and SDP
6
ligand, were developed and proved to be effective for the
7
12100, People’s Republic of China
ruthenium-catalyzed asymmetric hydrogenation. However, de-
velopment of more efficient catalyst systems comprised of more
readily accessible ligands of high enantioselectivity for practical
7
8
ReceiVed October 23, 2008
applications is still of significant importance for chemists.
Despite the great success that has been achieved, asymmetric
hydrogenation of ketones has not gained the same amount of
attention in practical applications as in academia. The main
obstacles include the use of a high level of metal catalysts, which
not only dramatically increases the cost but also raises serious
issues of heavy metal contamination. Thus it is necessary to
develop and demonstrate such catalytic systems that remain
effective even at an extremely low level without compromising
the selectivity. Herein, we would like to report our achievements
in the preparation of a wide variety of chiral alcohols in ideal-
approaching enantioselectivities (>99% ee for 13 examples)
The TunePhos/diamine-Ru(II) complex combined with
t-BuOK in 2-propanol effectively catalyzes enantioselective
hydrogenation of a wide range of simple ketones including
aromatic, heteroaromatic, R,ꢀ-unsaturated, and cyclopropyl
ketones, affording high reactivity (up to 1 000 000 TON) and
excellent enantioselectivities (>99% ee for 13 examples).
with only a ppm level of C
catalysts (TON up to 1 000 000).
Recently, we have developed a practical and convenient
synthetic route to prepare a series of air-stable modular C
3
*-TunePhos/diamine-Ru(II)
3
-
9
3
Tunephos-type chiral diphosphine ligands (C *-TunePhos),
which have been demonstrated earlier to be highly effective in
the hydrogenation N-substituted allylphthalimides and R-keto
Catalytic enantioselective hydrogenation of prochiral ketones
has been a powerful method to prepare enantiomerically pure
secondary alcohols, which are key structural elements in a large
9
c
esters. These ligands were designed to achieve superior
enantioselectivities for asymmetric hydrogenations utilizing their
highly modular nature. To illustrate potential utilities of Tune-
1
number of pharmaceutical products. For example, (R)-1-(3,5-
bis(trifluoromethyl)phenyl)ethanol is a key intermediate in the
(
4) Burk, M. J.; Hems, W.; Herzberg, D.; Malan, C.; Zanotti-Gerosa, A. Org.
synthesis of the neurokinin 1 (NK
1
) receptor antagonist Emend
Lett. 2000, 2, 4173.
2
(
Aprepitant; Scheme 1). This FDA-approved drug is for
(5) (a) Wu, J.; Chen, H.; Kwok, W.-H.; Guo, R.-W.; Zhou, Z.-Y; Yeung,
C.-H.; Chan, A. S. C. J. Org. Chem. 2002, 67, 7908. (b) Wu, J.; Ji, J.-X.; Guo,
R.-W.; Yeung, C.-H.; Chan, A. S. C. Chem. Eur. J. 2003, 9, 2963.
(6) Xie, J.-H.; Wang, L.-X; Fu, Y.; Zhu, S.-F.; Fan, B.-M.; Duan, H.-F.;
Zhou, Q.-L. J. Am. Chem. Soc. 2003, 125, 4404.
prevention of acute and delayed chemotherapy-induced nausea
and vomiting (CINV).
The milestone discoveries have been done by Noyori and
co-workers, who developed the BINAP-ruthenium-diamine
complexes as a highly effective catalyst system for asymmetric
(
7) (a) Cao, P.; Zhang, X. J. Org. Chem. 1999, 64, 2127. (b) Li, X.; Chen,
W.; Hems, W.; King, F.; Xiao, J. Org. Lett. 2003, 5, 4559. (c) Hu, A.; Ngo,
H. L.; Lin, W. Org. Lett. 2004, 6, 2937. (d) Genov, D. G.; Ager, D. J. Angew.
Chem., Int. Ed. 2004, 43, 2816. (e) Xu, Y.; Alcock, N. W.; Clarkson, G. J.;
Docherty, G.; Woodward, G.; Wills, M. Org. Lett. 2004, 6, 4105. (f) Burk, S.;
Franci o` , G.; Leitner, W. Chem. Commun. 2005, 3460. (g) Jing, Q.; Zhang, X.;
Sun, J.; Ding, K. AdV. Synth. Catal. 2005, 347, 1193.
(8) (a) Ohkuma, T.; Hattori, T.; Ooka, H.; Inoue, T.; Noyori, R. Org. Lett.
2004, 6, 2681. (b) Ohkuma, T.; Sandoval, C. A.; Srinivasan, R.; Lin, Q.; Wei,
Y.; Mu n˜ iz, K.; Noyori, R. J. Am. Chem. Soc. 2005, 127, 8288. (c) Arai, N.;
Suzuki, K.; Sugizaki, S.; Sorimachi, H.; Ohkuma, T. Angew. Chem., Int. Ed.
2008, 47, 1770.
(9) For general Tunephos structure, preparation and synthesis see: (a) Zhang,
X. U.S. Patent 6521769, September 19, 2000. (b) Zhang, Z.; Qian, H.; Longmire,
3
J.; Zhang, X. J. Org. Chem. 2000, 65, 6223. For the modular synthesis of C *-
TunePhos see: (c) Sun, X.; Zhou, L.; Li, W.; Zhang, X. J. Org. Chem. 2008, 73,
1143. (d) The ligand in catalyst 1c was also prepared by Chan et al., see: Qiu,
L.; Kwong, F. Y.; Wu, J.; Lam, W. H.; Chan, S.; Yu, W.-Y.; Li, Y.-M.; Guo,
R.; Zhou, Z.; Chan, A. S. C. J. Am. Chem. Soc. 2006, 128, 5955.
3
hydrogenation of ketones. Prompted by this fundamental study,
†
Rutgers, The State University of New Jersey.
Northwest A&F University.
‡
(
1) For reviews, see: (a) Noyori, R.; Ohkuma, T. Angew. Chem., Int. Ed.
2
001, 40, 40. (b) Noyori, R. AdV. Synth. Catal. 2003, 345, 15.
(
McNamara, J. M.; Ho, G.-J.; Emerson, K. M.; Song, Z. J.; Tschaen, D. M.;
2) (a) Hagmann, W. K. J. Med. Chem. 2008, 51, 4359. (b) Zhao, M. M.;
Brands, K. M. J.; Dolling, U.; Grabowski, E. J. J.; Reider, P. J. J. Org. Chem.
2
002, 67, 6743.
3) (a) Doucet, H.; Ohkuma, T.; Murata, K.; Yokozawa, T.; Kozawa, M.;
Katayama, E.; England, A. F.; Ikariya, T.; Noyori, R. Angew. Chem., Int. Ed.
998, 37, 1703. (b) Ohkuma, T.; Koizumi, M.; Doucet, H.; Pharm, T.; Kozawa,
(
1
M.; Murata, K.; Katayama, E.; Yokozawa, T.; Ikariya, T.; Noyori, R. J. Am.
Chem. Soc. 1998, 120, 13529.
1
0.1021/jo802372w CCC: $40.75 2009 American Chemical Society
J. Org. Chem. 2009, 74, 1397–1399 1397
Published on Web 12/31/2008